Details

Autor(en) / Beteiligte

• Anderson, Todd J., MD
• Grégoire, Jean, MD
• Pearson, Glen J., PharmD
• Barry, Arden R., PharmD
• Couture, Patrick, MD
• Dawes, Martin, MD
• Francis, Gordon A., MD
• Genest, Jacques, MD
• Grover, Steven, MD
• Gupta, Milan, MD
• Hegele, Robert A., MD
• Lau, David C., MD, PhD
• Leiter, Lawrence A., MD
• Lonn, Eva, MD
• Mancini, G.B. John, MD
• McPherson, Ruth, MD, PhD
• Ngui, Daniel, MD
• Poirier, Paul, MD, PhD
• Sievenpiper, John L., MD, PhD
• Stone, James A., MD, PhD
• Thanassoulis, George, MD
• Ward, Richard, MD

Titel

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

Ist Teil von

• Canadian journal of cardiology, 2016-11, Vol.32 (11), p.1263-1282

Ort / Verlag

England: Elsevier Inc

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Since the publication of the 2012 guidelines new literature has emerged to inform decision-making. The 2016 guidelines primary panel selected a number of clinically relevant questions and has produced updated recommendations, on the basis of important new findings. In subjects with clinical atherosclerosis, abdominal aortic aneurysm, most subjects with diabetes or chronic kidney disease, and those with low-density lipoprotein cholesterol ≥ 5 mmol/L, statin therapy is recommended. For all others, there is an emphasis on risk assessment linked to lipid determination to optimize decision-making. We have recommended nonfasting lipid determination as a suitable alternative to fasting levels. Risk assessment and lipid determination should be considered in individuals older than 40 years of age or in those at increased risk regardless of age. Pharmacotherapy is generally not indicated for those at low Framingham Risk Score (FRS; <10%). A wider range of patients are now eligible for statin therapy in the FRS intermediate risk category (10%-19%) and in those with a high FRS (> 20%). Despite the controversy, we continue to advocate for low-density lipoprotein cholesterol targets for subjects who start therapy. Detailed recommendations are also presented for health behaviour modification that is indicated in all subjects. Finally, recommendation for the use of nonstatin medications is provided. Shared decision-making is vital because there are many areas in which clinical trials do not fully inform practice. The guidelines are meant to be a platform for meaningful conversation between patient and care provider so that individual decisions can be made for risk screening, assessment, and treatment.